secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002721
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema nominates OP-3136, KAT6 inhibitor for breast cancer; IND submission targeted by end of 2024
--------------------------------------------------------------------------------

- OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor for ER+ breast cancer.
- Preclinical data show dose-dependent tumor regression alone and synergy with CDK4/6 or palazestrant.
- IND-enabling studies initiated; goal to file IND with FDA by end of 2024.
- Aurigene receives $5M milestone payment upon initiation of IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024002721/0000950170-24-002721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024002721/olma-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer